Most recent by Edward S. Kim, MD, MBA, FACP, FASCO
LOXO-101 shows promise for solid tumors with NTRK gene fusions
NEW ORLEANS — The investigational agent LOXO-101 demonstrated clinical activity in patients with solid tumors that had neurotrophic tyrosine receptor kinase gene fusions, according to study results presented at the American Association for Cancer Research Annual Meeting.
Radiofrequency ablation safe, effective for medically inoperable NSCLC
Radiofrequency ablation conferred 2-year OS rates comparable to stereotactic body radiotherapy in patients with medically inoperable non–small cell lung cancer, according to study results.
Second-line SBRT plus erlotinib extended survival in advanced NSCLC
Treatment with stereotactic body radiation therapy and erlotinib appeared highly effective in patients with metastatic stage IV non–small cell lung cancer who progressed on prior platinum-based chemotherapy, according to results of a single-arm phase 2 study.
CMS draft guidance allows access to lung cancer screening, requires safeguards
The CMS took a “responsible approach” when it issued its draft guidance for Medicare coverage of lung cancer screening for individuals who meet age and smoking history criteria, according to the primary requestor for the national coverage determination.
CMS supports Medicare coverage of lung cancer screening
The CMS today issued draft guidance that supports Medicare coverage of annual lung cancer screening with low-dose CT for individuals who meet specific criteria.
Two novel mutations linked to ALK inhibitor resistance in NSCLC
Two novel ALK mutations, V1180L and I1171T, were associated with resistance to crizotinib and alectinib but were sensitive to other next-generation ALK tyrosine kinase inhibitors for non–small-cell lung cancer, according to study results.